<?xml version="1.0" encoding="UTF-8"?>
<p id="Par9">Ribavirin is a synthetic nucleoside antiviral drug with broad-spectrum antiviral activity, which inhibits both DNA and RNA viruses and widely used for the treatment of SARS and MERS [
 <xref ref-type="bibr" rid="CR43">43</xref>, 
 <xref ref-type="bibr" rid="CR51">51</xref>–
 <xref ref-type="bibr" rid="CR53">53</xref>]. It was recommended that the combined use of ribavirin and α-interferon or lopinavir, 500 mg/time for adults with 2 to 3 intravenous injections per day, could control and improve patient’s condition, but the therapeutic process should be limited to 10 days [
 <xref ref-type="bibr" rid="CR32">32</xref>]. Notably, patients with contraindications should be excluded before clinical application for the reason that the incidence of adverse reactions of ribavirin is high and the individualized differences are obvious [
 <xref ref-type="bibr" rid="CR54">54</xref>]. Studies on the effect of ribavirin in vitro showed that ribavirin could reduce viral infection [
 <xref ref-type="bibr" rid="CR55">55</xref>]. However, the effectiveness and safety of ribavirin for COVID-19 still need further clinical trials to confirm. Medical workers should carefully and comprehensively evaluate the patient’s various indicators to ensure the safety of patients’ medication.
</p>
